Related Experiment Video
Updated: Aug 6, 2025
05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
249
[GLP-1 and GIP receptor agonists: emerging therapies for obesity]
Dionysios Chartoumpekis1, Lucie Favre1
1Service d'endocrinologie, diabétologie et métabolisme, Département de médecine, Centre hospitalier universitaire vaudois, 1011 Lausanne.
Revue Medicale Suisse
|March 23, 2023
Summary
New obesity treatments targeting appetite regulation, like GLP-1 and dual GIP/GLP-1 therapies, offer significant weight loss beyond surgery. These advancements provide hope for managing this chronic metabolic disease.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Context:
- Obesity is a complex metabolic disease with severe health consequences.
- Bariatric surgery was the primary method for substantial, lasting weight reduction.
- Advances in understanding appetite regulation have spurred novel therapeutic development.
Purpose:
- To summarize the mechanisms of action for new obesity medications.
- To review clinical data supporting the efficacy of these treatments.
- To highlight the role of incretin-based therapies in weight management.
Summary:
- Glucagon-like peptide-1 (GLP-1) receptor agonists are established obesity treatments.
- Dual therapies combining GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) analogues show enhanced weight loss.
- These agents target the endocrine regulation of appetite for metabolic control.
Impact:
- Provides an overview of emerging pharmacological treatments for obesity.
- Supports the clinical use of incretin mimetics for significant weight reduction.
- Offers alternatives for patients seeking alternatives or adjuncts to bariatric surgery.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
378
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
378
01:23Dipeptidyl Peptidase 4 Inhibitors
222
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
222
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
248
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
248
01:06Oral Hypoglycemic Agents: Glinides
199
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
199
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
224
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
224
01:15G Protein-coupled Receptors
12.5K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
12.5K